MedTrace Logo

Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections

NCT03160807 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2017-05-19

No results posted yet for this study

Summary

Study is planned to evaluate safety and efficacy of Levolet in patients with complicated UTI

Conditions

Interventions

DRUG

Levofloxacin

Levolet 500 mg OD for 5 days

DRUG

Levofloxacin

Levolet 500 OD for 10 days

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Principal Investigators

  • Dr Ilyas Tungiskhanovich · Scientific Centre of Urology named after B.U Dzharbusynov 2, Basenov street, Almaty 050060, Republic of Kazakhstan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-15
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03160807 on ClinicalTrials.gov